RSS Feeds
Coenzyme Q10 and Congestive Heart Failure
- Stephen S. Gottlieb, MD;
- Meenakshi Khatta, MS, CRNP; and
- Michael L. Fisher, MD
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
IN RESPONSE:
The use of coenzyme Q10 in congestive heart failure continues to be advocated on the basis of anecdotal information and uncontrolled data. Dr. Sinatra's letter uses unsubstantiated theoretical concerns to ignore and discount the implications of a negative controlled trial. It is possible that higher concentrations of a substance might be more beneficial than lower concentrations. Nevertheless, in patients with heart failure, most drugs that are useful at high doses are also effective at lower doses. To use Dr. Sinatra's example, patients receiving angiotensin-converting enzyme inhibitors have fewer hospitalizations when the drug is given at a high dose, but these drugs are clearly of benefit with lower doses (1). Similarly, β-blockers are effective at low doses, although higher doses appear more beneficial (2). If coenzyme Q10 blood concentrations of 2.9 µg/mL are truly optimal, concentrations that are slightly lower but more than double the baseline level (as realized and documented in our study) should still be effective. No published data indicate that the coenzyme Q10 concentrations needed for patients with heart failure are higher than those achieved in our study. As discussed in our article, studies advocating coenzyme Q10 for heart failure have used doses lower than those we administered. Furthermore, mean serum concentrations more than doubled in our study to 2.2 µg/mL, higher than the concentration achieved in the study (3) quoted by Dr. Sinatra. The authors of that study concluded that concentrations of 2.5 µg/mL are optimal, but they provided no data to support this conclusion. Other experiences quoted by Dr. Sinatra are also anecdotal.
Regarding duration of treatment, even the study cited by Dr. Sinatra suggests that 3 months should be enough time to see a benefit (3). We administered coenzyme Q10 for 6 months.
We are most concerned that Dr. Sinatra may be implying that high doses of coenzyme Q10 might be preferable to β-blockade in patients with heart failure. β-Blockers substantially improve both mortality and morbidity in patients with heart failure (4). This treatment has been well studied, and the data are conclusive. In contrast, supporters of the use of coenzyme Q10 can point only to small uncontrolled studies and theoretical concerns. We have no objection to further controlled studies of coenzyme Q10. Meanwhile, using anecdotal experience to advocate the use of expensive high doses of a drug shown to be ineffective in controlled studies is inappropriate.
Stephen S. Gottlieb, MD
Meenakshi Khatta, MS, CRNP
Michael L. Fisher, MD
University of Maryland; Baltimore, MD 21201
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
- Copyright ©2004 by the American College of Physicians
